DOGenes Inc.

AI summary of RD research at DOGenes

Scientific Terms used in the description are a follows:
A promoter is a sequence of DNA to which proteins bind to control the when, where and how much protein is produced. This sequence is located before the DNA sequence that codes for a protein. DNA methylation changes the chemical composition of the promoter and prevents binding of the proteins that control the expression of the gene. This results in less protein than the wild type (normal) gene.

The search terms refer directly to a prominent peer-reviewed study authored by Dr. Mary H. Whiteley, published in the journal Clinical Epigenetics. The paper is titled "Allelic variation in the canine Cox-2 promoter causes hypermethylation of the canine Cox-2 promoter in clinical cases of renal dysplasia". [1]

Core Findings of the Whiteley Study

•    Disease Link: Dr. Whiteley's research established that specific insertion/deletion mutant alleles in the promoter region of the canine cyclooxygenase-2 (Cox-2) gene predispose dogs to canine renal dysplasia (RD), a developmental kidney disease. [1, 2]

•    Epigenetic Downregulation: In clinically affected dogs, these genomic variants trigger hypermethylation of the Cox-2 promoter. This epigenetic modification effectively silences or represses gene expression. [1, 2]

•    Selective Methylation: The wild-type (normal) allele is never methylated, even in heterozygous carrier dogs that possess one mutant allele. Furthermore, dogs that possess the mutation but are "biopsy-negative" (asymptomatic) do not exhibit this methylation pattern. [1, 2]

•    Early Embryonic Origin: Because identical methylated Cox-2 promoter DNA sequences are found across various adult tissue types rather than just the kidneys, this epigenetic silencing must occur early during embryogenesis before germ-line cell differentiation. [1, 2]

•    Phenotypic Variation: The extent of the DNA methylation varies between individual dogs, explaining the highly complex, variable clinical presentations and incomplete penetrance of renal dysplasia in canine populations. [1, 2]

Clinical Application
Based on this research, a commercial diagnostic Cox-2 DNA test was developed by DOGenes Inc., a genetic testing company founded by Whiteley and located in Peterborough, Ontario. The test identifies the presence of these Cox-2 promoter variants to evaluate genetic risk in susceptible dog breeds. However, the broader veterinary community notes that the DNA test evaluates predisposition rather than a definitive diagnosis, which still relies heavily on clinical ultrasound, blood chemistry, and physical renal wedge biopsies. [1, 2, 3]

NOTE:
The test screens breeds susceptible to renal dysplasia—such as Shih tzus, Lhasa Apsos, and Golden Retrievers—for these specific Cox-2 promoter variants to help breeders prevent the disease. [1, 2, 3]

Another AI summary describes this research as:
The search terms refer to landmark veterinary genetics research by Dr. Mary H. Whiteley, which demonstrated that allelic variation in the promoter of the canine cyclooxygenase-2 (Cox-2) gene causes hypermethylation and gene silencing, leading to clinical canine renal dysplasia (RD). [1, 2]
Her key publication on this topic is titled "Allelic variation in the canine Cox-2 promoter causes hypermethylation of the canine Cox-2 promoter in clinical cases of renal dysplasia". [1, 2]

References:
1. Whiteley, Mary H. "Allelic variation in the canine Cox-2 promoter causes hypermethylation of the canine Cox-2 promoter in clinical cases of renal dysplasia." Clinical Epigenetics 6.1 (2014): 7.

2, Whiteley, Mary H., Jerold S. Bell, and Debby A. Rothman. "Novel allelic variants in the canine cyclooxgenase-2 (Cox-2) promoter are associated with renal dysplasia in dogs." PLoS One 6.2 (2011): e16684.

CONTRADICTIONS IN THE SCIENTIFIC RECORD:

Continued on next page.